Lee Ainslie's BMY Position Overview
Lee Ainslie (via Maverick Capital LTD) currently holds 34,008 shares of Bristol-Myers Squibb Company (BMY) worth $2.12 M, representing 0.02% of the portfolio. First purchased in 2018-Q3, this medium-term investment has been held for 13 quarters.
Based on 13F filings, Lee Ainslie has maintained a strategic position in BMY, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2019, adding 138,060 shares. Largest reduction occurred in Q4 2018, reducing 148,610 shares.
Analysis based on 13F filings available since 2013 Q2
Lee Ainslie's Bristol-Myers Squibb Company (BMY) Holding Value Over Time
Track share changes against reported price movement
Quarterly Bristol-Myers Squibb Company (BMY) Trades by Lee Ainslie
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2026 | +34,008 | New Buy | 34,008 | $62.40 |
| Q2 2021 | -40,241 | Sold Out | 0 | $0.00 |
| Q1 2021 | +17,692 | Add 78.46% | 40,241 | $63.12 |
| Q4 2020 | +15,382 | Add 214.62% | 22,549 | $62.04 |
| Q3 2020 | -58,206 | Reduce 89.04% | 7,167 | $60.28 |
| Q2 2020 | -3,580 | Reduce 5.19% | 65,373 | $58.80 |
| Q1 2020 | -46,300 | Reduce 40.17% | 68,953 | $55.73 |
| Q4 2019 | -9,259 | Reduce 7.44% | 115,253 | $64.19 |
| Q3 2019 | +3,512 | Add 2.90% | 124,512 | $50.71 |
| Q2 2019 | -17,060 | Reduce 12.36% | 121,000 | $45.35 |
| Q1 2019 | +138,060 | New Buy | 138,060 | $47.71 |
| Q4 2018 | -148,610 | Sold Out | 0 | $0.00 |
| Q3 2018 | +148,610 | New Buy | 148,610 | $62.08 |
Lee Ainslie's Bristol-Myers Squibb Company Investment FAQs
Lee Ainslie first purchased Bristol-Myers Squibb Company (BMY) in Q3 2018, acquiring 148,610 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Lee Ainslie has held Bristol-Myers Squibb Company (BMY) for 13 quarters since Q3 2018.
Lee Ainslie's largest addition to Bristol-Myers Squibb Company (BMY) was in Q3 2018, adding 148,610 shares worth $9.23 M.
According to the latest 13F filing for Q3 2026, Lee Ainslie's firm, Maverick Capital LTD, owns 34,008 shares of Bristol-Myers Squibb Company (BMY), valued at approximately $2.12 M.
As of the Q3 2026 filing, Bristol-Myers Squibb Company (BMY) represents approximately 0.02% of Lee Ainslie's publicly disclosed stock portfolio, making it one of their key holdings.
Lee Ainslie's peak holding in Bristol-Myers Squibb Company (BMY) was 148,610 shares, as reported at the end of Q3 2018.